Join Growin Stock Community!

Actuate therapeutics incACTU.US Overview

US StockHealthcare
(No presentation for ACTU)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ACTU AI Insights

ACTU Overall Performance

ACTU AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ACTU Recent Performance

-2.94%

Actuate therapeutics inc

0.05%

Avg of Sector

-0.31%

S&P500

ACTU PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ACTU Key Information

ACTU Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ACTU Profile

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Price of ACTU

ACTU FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ACTU Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.04
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
8.53
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.04
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
8.53
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ACTU's latest earnings report released?

    The most recent financial report for Actuate therapeutics inc (ACTU) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ACTU's short-term business performance and financial health. For the latest updates on ACTU's earnings releases, visit this page regularly.

  • How much cash does ACTU have?

    At the end of the period, Actuate therapeutics inc (ACTU) held Total Cash and Cash Equivalents of 16.92M, accounting for 0.96 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ACTU's EPS continuing to grow?

    According to the past four quarterly reports, Actuate therapeutics inc (ACTU)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.25. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ACTU?

    Actuate therapeutics inc (ACTU)'s Free Cash Flow (FCF) for the period is -6.68M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 27.01% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ACTU?

    The latest valuation data shows Actuate therapeutics inc (ACTU) has a Price-To-Earnings (PE) ratio of -5.67 and a Price/Earnings-To-Growth (PEG) ratio of 0.4. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.